Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03151408




Registration number
NCT03151408
Ethics application status
Date submitted
5/05/2017
Date registered
12/05/2017
Date last updated
10/03/2022

Titles & IDs
Public title
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Scientific title
A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients =18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy
Secondary ID [1] 0 0
PRAN-16-52
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Acute Myeloid Leukemia 0 0
Condition category
Condition code
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Pracinostat
Treatment: Drugs - Placebos
Treatment: Drugs - Azacitidine

Experimental: Pracinostat plus AZA - 60 mg capsule orally, once a day, 3 times a week for 3 weeks, followed by 1 week of rest of each 28-day cycle. As a background therapy azacitidine (AZA) will be administered at a dose of 75 mg/m2 by SC or IV injection daily for 7 days of each 28-day cycle.

Placebo Comparator: Placebo plus AZA - 1 capsule orally, once a day, 3 times a week for 3 weeks, followed by 1 week of rest of each 28-day cycle. As a background therapy azacitidine (AZA) will be administered at a dose of 75 mg/m2 by SC or IV injection daily for 7 days of each 28-day cycle.


Treatment: Drugs: Pracinostat
60 mg capsule

Treatment: Drugs: Placebos
capsule

Treatment: Drugs: Azacitidine
SC or IV injection
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival
Timepoint [1] 0 0
826 days
Secondary outcome [1] 0 0
Morphologic Complete Remission (CR) Rate
Timepoint [1] 0 0
744 days
Secondary outcome [2] 0 0
Complete Remission Without Minimal Residual Disease (CRmrd) Rate
Timepoint [2] 0 0
826 days
Secondary outcome [3] 0 0
Cytogenetic Complete Remission (CRc) Rate
Timepoint [3] 0 0
826 days
Secondary outcome [4] 0 0
Transfusion Independence (TI)
Timepoint [4] 0 0
826 days

Eligibility
Key inclusion criteria
1. Male or female patient = 18 years of age with newly diagnosed, histologically or
cytologically confirmed, AML including de novo, secondary to antecedent hematologic
disorders, or treatment-related disease with intermediate or unfavorable-risk
cytogenetics

2. Unable to receive intensive chemotherapy regimens at enrollment, based on one of the
following:

I. Age = 75 years, or

II. Age < 75 years with at least 1 of the following co-morbidities:

1. An ECOG performance status of 2

2. Clinically significant cardiovascular disease defined as:

i. Left ventricular ejection fraction (LVEF) = 50%, measured within 3 months prior to
Day 1 confirmed by ECHO/MUGA ii. Congestive heart failure requiring medical therapy
iii. Chronic stable angina requiring medical therapy iv. Prior cerebrovascular
accident with sequelae c. Clinically significant pulmonary disease defined as: i.
Forced expiratory volume in 1 second (FEV1) = 65% of expected ii. Lung diffusing
capacity for carbon monoxide (DLCO) = 65% of expected Confirmed by pulmonary tests. d.
Diabetes mellitus with symptomatic end-organ damage (e.g., retinopathy, nephropathy,
neuropathy, vasculopathy) e. Autoimmune inflammatory conditions (e.g., rheumatoid
arthritis, systemic lupus erythematous, inflammatory bowel disease, or similar)
requiring chronic disease modifying therapy (e.g., etanercept, adalimumab, infliximab,
rituximab, methotrexate, or similar) f. Class III obesity defined as a Body Mass Index
(BMI) > 40 kg/m2 g. Renal impairment defined as serum creatinine > 1.3 mg/dL (> 115
µmol/L) or creatinine clearance <70 ml/min h. Clinically significant cognitive
impairment defined as requiring medical therapy and/or assistance with activities of
daily living

3. 20% blasts in bone marrow

4. Peripheral white blood cell (WBC) count 30,000/µL For cyto-reduction, hydroxyurea is
allowed during screening and up to Cycle 1, Days 1-14, to reduce WBC count to < 30,000
µL prior to Day 1. After Cycle 1, Day 14, hydroxyurea is prohibited.

5. ECOG performance status = 2

6. Adequate organ function as evidenced by the following laboratory findings:

1. Total bilirubin = 2 × upper limit of normal (ULN) or < 3 x ULN for patients with
Gilbert-Meulengracht Syndrome

2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5 × ULN

7. Serum creatinine = 1.5 × ULN according to institutional standards or creatinine
clearance = 50 mL/min

8. QT-interval corrected according to Fridericia's formula (QTcF) = 450 ms on
electrocardiogram (ECG) at Screening

9. Male patient who is surgically sterile, or male patient who is willing to agree to
remain completely abstinent (refrain from heterosexual intercourse) or who use barrier
contraceptive measures and agree to refrain from donating sperm during the entire
study treatment period and for 3 months after the last administration of study drug

10. Female patient who is of childbearing potential willing to use adequate contraceptive
measures while participating on study, OR willing to completely abstain from
heterosexual intercourse during the entire study treatment period

11. Female patient who is of childbearing potential must have a negative serum pregnancy
test result within 3 weeks prior to starting study drugs.

12. Willing to provide voluntary written informed consent before performance of any study
related procedure not part of normal medical care

13. Willing and able to understand the nature of this study and to comply with the study
and follow-up procedures.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Able to receive intensive induction chemotherapy

2. AML-associated inv(16)/t(16;16)/del(16q), t(15;17) (i.e. promyelocytic leukemia)
with/without secondary aberrations; t(8;21) lacking del (9q) or complex karyotypes

3. Presence of an active malignant disease within the last 12 months, with the exception
of adequately treated cervical cancer in-situ, non-melanoma skin cancer and
superficial bladder tumors (Ta [non-invasive tumor], Tis [carcinoma in situ] and T1
[tumor invades lamina propria]). Other malignancies may be considered after
consultation with the Medical Monitor

4. Life-threatening illnesses other than AML, uncontrolled medical conditions or organ
system dysfunction that, in the Investigator's opinion, could compromise the patient's
safety or put the study outcomes at risk

5. Uncontrolled arrhythmias; any Class 3-4 cardiac diseases as defined by the New York
Heart Association (NYHA) functional classification

6. Evidence of AML central nervous system (CNS) involvement

7. Previous chemotherapy for AML except for the following, which are allowed:

1. Hydroxyurea for cytoreduction

2. One course of hypomethylating agent therapy (i.e.; up to 7 doses of azacitidine
or 3-5 days of decitabine) within 30 days prior to enrollment (Day 1)

8. Use of experimental drugs = 30 days prior to screening

9. Received prior HDAC inhibitor therapy

10. Received prior treatment with a hypomethylating agent, except as allowed in Exclusion
Criterion 7.b

11. Known hypersensitivity to any components of pracinostat, azacitidine, or mannitol

12. History of human immunodeficiency virus (HIV) or an active and uncontrolled infection
with hepatitis C virus (HCV) or hepatitis B virus (HBV)

13. Gastrointestinal (GI) tract disease that causes an inability to take oral medication,
malabsorption syndrome, or a requirement for IV alimentation; prior surgical
procedures affecting absorption; or uncontrolled inflammatory GI disease (e.g.,
Crohn's disease, ulcerative colitis)

14. Any disease(s), psychiatric condition, metabolic dysfunction, or findings from a
physical examination or clinical laboratory test result that would cause reasonable
suspicion of a disease or condition, that contraindicates the use of pracinostat
and/or AZA, that may increase the risk associated with study participation, that may
affect the interpretation of the results, or that would make the patient inappropriate
for this study

15. Breast-feeding woman

16. current smokers(use of patches, chewing gums and vaping nicotine conaining fluids is
permitted). Patients who stopped smoking at least 8 day prior to first pracinostat
dosing can be enrolled, provided they refrain from smoking during the whole study

17. prohibited concomitant medications

18. uncontrolled infections

19. receive more than 1 prior cycle of HMA or bone marrow transplant for any prior
hematological disorder antecedent to AML

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
23/06/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
20/08/2020
Sample size
Target
Accrual to date
Final
406
Recruitment in Australia
Recruitment state(s)
NSW,QLD,TAS,VIC
Recruitment hospital [1] 0 0
Liverpool Hospital - Liverpool
Recruitment hospital [2] 0 0
Sunshine coast university hospital - Birtinya
Recruitment hospital [3] 0 0
Royal Hobart Hospital - Hobart
Recruitment hospital [4] 0 0
The Northern hospital Pharmacy Department, Ground Floor - Epping
Recruitment hospital [5] 0 0
Barwon Health, University Hospital Geelong - Geelong
Recruitment hospital [6] 0 0
Austin Hospital, Clinical Trial Pharmacy - Heidelberg
Recruitment hospital [7] 0 0
Liverpool hospital - Liverpool
Recruitment hospital [8] 0 0
Royal Perth Hospital - Perth
Recruitment hospital [9] 0 0
Prince of Wales Hospital - Randwick
Recruitment postcode(s) [1] 0 0
2170 - Liverpool
Recruitment postcode(s) [2] 0 0
4575 - Birtinya
Recruitment postcode(s) [3] 0 0
7000 - Hobart
Recruitment postcode(s) [4] 0 0
3076 - Epping
Recruitment postcode(s) [5] 0 0
3220 - Geelong
Recruitment postcode(s) [6] 0 0
3084 - Heidelberg
Recruitment postcode(s) [7] 0 0
6000 - Perth
Recruitment postcode(s) [8] 0 0
2031 - Randwick
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
District of Columbia
Country [4] 0 0
United States of America
State/province [4] 0 0
Idaho
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Kansas
Country [7] 0 0
United States of America
State/province [7] 0 0
Kentucky
Country [8] 0 0
United States of America
State/province [8] 0 0
Louisiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Minnesota
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
Montana
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oklahoma
Country [19] 0 0
United States of America
State/province [19] 0 0
South Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Tennessee
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Virginia
Country [23] 0 0
United States of America
State/province [23] 0 0
Washington
Country [24] 0 0
Argentina
State/province [24] 0 0
Buenos Aires
Country [25] 0 0
Argentina
State/province [25] 0 0
Santa Fe
Country [26] 0 0
Argentina
State/province [26] 0 0
Córdoba
Country [27] 0 0
Austria
State/province [27] 0 0
Linz
Country [28] 0 0
Austria
State/province [28] 0 0
Salzburg
Country [29] 0 0
Austria
State/province [29] 0 0
Vienna
Country [30] 0 0
Brazil
State/province [30] 0 0
Paranà
Country [31] 0 0
Brazil
State/province [31] 0 0
SP
Country [32] 0 0
Brazil
State/province [32] 0 0
Barretos
Country [33] 0 0
Brazil
State/province [33] 0 0
Belo Horizonte
Country [34] 0 0
Brazil
State/province [34] 0 0
Florianópolis
Country [35] 0 0
Brazil
State/province [35] 0 0
Porto Alegre
Country [36] 0 0
Brazil
State/province [36] 0 0
Rio De Janeiro
Country [37] 0 0
Brazil
State/province [37] 0 0
Santo André
Country [38] 0 0
Brazil
State/province [38] 0 0
São José Do Rio Preto
Country [39] 0 0
Czechia
State/province [39] 0 0
Hradec Králové
Country [40] 0 0
Czechia
State/province [40] 0 0
Olomouc
Country [41] 0 0
Czechia
State/province [41] 0 0
Praha 2
Country [42] 0 0
Czechia
State/province [42] 0 0
Praha
Country [43] 0 0
France
State/province [43] 0 0
Amiens
Country [44] 0 0
France
State/province [44] 0 0
Nantes
Country [45] 0 0
France
State/province [45] 0 0
Nice
Country [46] 0 0
France
State/province [46] 0 0
Paris
Country [47] 0 0
France
State/province [47] 0 0
Pessac
Country [48] 0 0
France
State/province [48] 0 0
Pierre-Bénite
Country [49] 0 0
France
State/province [49] 0 0
Rouen Cedex 1
Country [50] 0 0
Germany
State/province [50] 0 0
Bavaria
Country [51] 0 0
Germany
State/province [51] 0 0
Bayern
Country [52] 0 0
Germany
State/province [52] 0 0
North Rhine-westphalia
Country [53] 0 0
Germany
State/province [53] 0 0
Berlin
Country [54] 0 0
Germany
State/province [54] 0 0
Chemnitz
Country [55] 0 0
Germany
State/province [55] 0 0
Gera
Country [56] 0 0
Germany
State/province [56] 0 0
Kiel
Country [57] 0 0
Germany
State/province [57] 0 0
Mainz
Country [58] 0 0
Hungary
State/province [58] 0 0
Baranya
Country [59] 0 0
Hungary
State/province [59] 0 0
Budapest
Country [60] 0 0
Hungary
State/province [60] 0 0
Debrecen
Country [61] 0 0
Hungary
State/province [61] 0 0
Kaposvár
Country [62] 0 0
Hungary
State/province [62] 0 0
Nyiregyhaza
Country [63] 0 0
Italy
State/province [63] 0 0
Lombardia
Country [64] 0 0
Italy
State/province [64] 0 0
PA
Country [65] 0 0
Italy
State/province [65] 0 0
Bari
Country [66] 0 0
Italy
State/province [66] 0 0
Bologna
Country [67] 0 0
Italy
State/province [67] 0 0
Firenze
Country [68] 0 0
Italy
State/province [68] 0 0
Genova
Country [69] 0 0
Italy
State/province [69] 0 0
Lecce
Country [70] 0 0
Italy
State/province [70] 0 0
Naples
Country [71] 0 0
Italy
State/province [71] 0 0
Napoli
Country [72] 0 0
Italy
State/province [72] 0 0
Pavia
Country [73] 0 0
Italy
State/province [73] 0 0
Roma
Country [74] 0 0
Italy
State/province [74] 0 0
Torino
Country [75] 0 0
Korea, Republic of
State/province [75] 0 0
Busan
Country [76] 0 0
Korea, Republic of
State/province [76] 0 0
Hwasun
Country [77] 0 0
Korea, Republic of
State/province [77] 0 0
Incheon
Country [78] 0 0
Korea, Republic of
State/province [78] 0 0
Seoul
Country [79] 0 0
Korea, Republic of
State/province [79] 0 0
Ulsan
Country [80] 0 0
Poland
State/province [80] 0 0
Poznan
Country [81] 0 0
Poland
State/province [81] 0 0
Walbrzych
Country [82] 0 0
Poland
State/province [82] 0 0
Wroclaw
Country [83] 0 0
Poland
State/province [83] 0 0
Lódz
Country [84] 0 0
Romania
State/province [84] 0 0
Jud.dolj
Country [85] 0 0
Romania
State/province [85] 0 0
Bucuresti
Country [86] 0 0
Romania
State/province [86] 0 0
Cluj-Napoca
Country [87] 0 0
Romania
State/province [87] 0 0
Iasi
Country [88] 0 0
Spain
State/province [88] 0 0
Barcelona
Country [89] 0 0
Spain
State/province [89] 0 0
Extremadura
Country [90] 0 0
Spain
State/province [90] 0 0
Galicia
Country [91] 0 0
Spain
State/province [91] 0 0
Isla Baleares
Country [92] 0 0
Spain
State/province [92] 0 0
Madrid
Country [93] 0 0
Spain
State/province [93] 0 0
Salamanca
Country [94] 0 0
Spain
State/province [94] 0 0
Sevilla
Country [95] 0 0
Spain
State/province [95] 0 0
Valencia
Country [96] 0 0
Taiwan
State/province [96] 0 0
Changhua
Country [97] 0 0
Taiwan
State/province [97] 0 0
Kaohsiung
Country [98] 0 0
Taiwan
State/province [98] 0 0
Taichung
Country [99] 0 0
Taiwan
State/province [99] 0 0
Taipei
Country [100] 0 0
United Kingdom
State/province [100] 0 0
Devon
Country [101] 0 0
United Kingdom
State/province [101] 0 0
Lancashire
Country [102] 0 0
United Kingdom
State/province [102] 0 0
Bradford
Country [103] 0 0
United Kingdom
State/province [103] 0 0
Coventry
Country [104] 0 0
United Kingdom
State/province [104] 0 0
Liverpool

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Helsinn Healthcare SA
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Clinipace Worldwide
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase III, multicenter, double-blind, randomized study of pracinostat vs. placebo
with azacitidine (AZA) as background therapy in patients = 18 years of age with newly
diagnosed acute myeloid leukemia (AML), excluding acute promyelocytic leukemia and
cytogenetic low-risk AML, who are unfit to receive intensive remission induction chemotherapy
due to age = 75 years or comorbidities. Patients will be randomized in a 1:1 ratio to one of
two groups: Group A (experimental group) to receive pracinostat plus AZA and Group B (control
group) to receive placebo plus AZA. Randomization will be stratified by cytogenetic risk
category (intermediate vs. unfavorable-risk, according to SWOG Cytogenetic Risk Category
Definitions) and ECOG performance status (0-1 vs. 2). Treatments will be administered based
on 28-day cycles, with pracinostat/placebo administered orally once every other day, 3 times
a week for 3 weeks, followed by one week of no treatment and AZA administered for 7 days of
each cycle. Study treatment should continue until there is documented disease progression,
relapse from complete remission (CR), or non-manageable toxicity. A minimum of 6 cycles may
be required to achieve a complete remission. Once permanently discontinued from study
treatment, patients will enter the Long-term Follow-up phase of the study and will be
followed for assessment of disease progression, if applicable, and survival every 3 months
(±1 month) until death. The end of this study is defined when 390 events (deaths) have
occurred and the study is unblinded for final overall survival analysis. Patients who are
receiving study treatment at the end of the study may have the opportunity to continue to
receive the study drugs to which they were randomized to (Post- Study Observation Period),
until the Sponsor informs the Investigators of the appropriate course of action based on the
study results. The Post-Study Observation Period is defined as the period starting from the
end of the study for a maximum of 12 months.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03151408
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Guillermo Garcia-Manero, MD
Address 0 0
MD Anderson
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03151408